Abcellera Biologics Inc (ABCL)vsRoyalty Pharma Plc (RPRX)
ABCL
Abcellera Biologics Inc
$5.74
-11.77%
HEALTHCARE · Cap: $1.60B
RPRX
Royalty Pharma Plc
$54.28
-1.93%
HEALTHCARE · Cap: $31.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 2981% more annual revenue ($2.44B vs $79.21M). RPRX leads profitability with a 33.9% profit margin vs -181.7%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
ABCL
Hold41
out of 100
Grade: D
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.7%
Fair Value
$8.86
Current Price
$5.74
$3.12 discount
Margin of Safety
-57.2%
Fair Value
$34.53
Current Price
$54.28
$19.75 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 96.3% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Earnings expanding 45.9% YoY
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -15.3% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABCL
The strongest argument for ABCL centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 96.3% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : ABCL
The primary concerns for ABCL are Altman Z-Score, Market Cap, Return on Equity.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
ABCL profiles as a hypergrowth stock while RPRX is a mature play — different risk/reward profiles.
ABCL carries more volatility with a beta of 1.20 — expect wider price swings.
ABCL is growing revenue faster at 96.3% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 41/100), backed by strong 33.9% margins and 11.0% revenue growth. ABCL offers better value entry with a 64.7% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abcellera Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
Visit Website →Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?